QuidelOrtho Announces Grant of Equity Awards to New Employees
In a recent announcement made by QuidelOrtho Corporation, a prominent global player in diagnostic solutions, the company has revealed that its Board of Directors has approved the grant of equity awards to two newly onboarded, non-executive employees. This step comes under the Company's 2026 Inducement Plan, aimed to incentivize these new hires as they commence their employment with the organization, aligning with the stipulations set forth by Nasdaq Listing Rule 5635(c)(4).
The 2026 Inducement Plan is uniquely designed to facilitate the granting of equity awards specifically to individuals who are joining QuidelOrtho for the first time or returning after a genuine period of non-employment. This plan serves as a crucial inducement that emphasizes the importance of attracting top talent in the competitive landscape of the diagnostic solutions industry.
The awards granted consist of restricted stock units (RSUs) which are linked to a collective total of 50,323 shares of QuidelOrtho's common stock. These RSUs were allocated on the grant date, October 15, 2026, with a vesting schedule that will see them matured in equal portions over three years. To qualify for the vesting, the employees are required to maintain their employment with the company throughout each applicable vesting date. Furthermore, the RSUs are bound by the guidelines of the 2026 Inducement Plan along with individual RSU award agreements tailored for each grant.
QuidelOrtho Corporation has established a strong commitment to advancing diagnostic technologies that foster a healthier future. The firm aims to provide swift, precise, and dependable results that enhance patient care, whether in clinical settings, laboratories, or hospitals. With an accumulated expertise across various domains such as clinical chemistry, immunoassay, immunohematology, and molecular testing, QuidelOrtho is recognized for its legacy of innovation in diagnostic solutions. This dedication enables healthcare professionals to make well-informed decisions that lead to improved patient outcomes.
Prospective investors and interested stakeholders are encouraged to learn more about QuidelOrtho’s operations and objectives by visiting their official website at quidelortho.com. The company actively engages with audiences across multiple platforms, including LinkedIn, Facebook, and X, to foster transparency and community connections.
For inquiries regarding investor relations, Sanjeev Sharma, Vice President of Investor Relations, is available for contact. Media inquiries can be directed to Stephanie Kleewein, the Senior Corporate Communication and PR Manager, to further explore the company's initiatives and achievements in the field of diagnostic solutions.
The 2026 Inducement Plan is uniquely designed to facilitate the granting of equity awards specifically to individuals who are joining QuidelOrtho for the first time or returning after a genuine period of non-employment. This plan serves as a crucial inducement that emphasizes the importance of attracting top talent in the competitive landscape of the diagnostic solutions industry.
The awards granted consist of restricted stock units (RSUs) which are linked to a collective total of 50,323 shares of QuidelOrtho's common stock. These RSUs were allocated on the grant date, October 15, 2026, with a vesting schedule that will see them matured in equal portions over three years. To qualify for the vesting, the employees are required to maintain their employment with the company throughout each applicable vesting date. Furthermore, the RSUs are bound by the guidelines of the 2026 Inducement Plan along with individual RSU award agreements tailored for each grant.
QuidelOrtho Corporation has established a strong commitment to advancing diagnostic technologies that foster a healthier future. The firm aims to provide swift, precise, and dependable results that enhance patient care, whether in clinical settings, laboratories, or hospitals. With an accumulated expertise across various domains such as clinical chemistry, immunoassay, immunohematology, and molecular testing, QuidelOrtho is recognized for its legacy of innovation in diagnostic solutions. This dedication enables healthcare professionals to make well-informed decisions that lead to improved patient outcomes.
Prospective investors and interested stakeholders are encouraged to learn more about QuidelOrtho’s operations and objectives by visiting their official website at quidelortho.com. The company actively engages with audiences across multiple platforms, including LinkedIn, Facebook, and X, to foster transparency and community connections.
For inquiries regarding investor relations, Sanjeev Sharma, Vice President of Investor Relations, is available for contact. Media inquiries can be directed to Stephanie Kleewein, the Senior Corporate Communication and PR Manager, to further explore the company's initiatives and achievements in the field of diagnostic solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.